Mounjaro® (tirzepatide) is an innovative injectable medication designed for weight loss and blood sugar control. It mimics natural GLP-1 and GIP hormones in your gut, helping control your appetite and making you feel fuller for longer. When paired with a reduced-calorie diet and increased physical activity, it results in effective, healthy weight loss.

Mounjaro® is a dual GIP and GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon levels, slows gastric emptying, reduces appetite, and increases feelings of fullness, helping control blood sugar levels and promote weight loss.

Mounjaro® is suitable for adults with a BMI over 30 or a BMI over 27 with weight-related health concerns such as high blood pressure, diabetes, heart disease, or raised cholesterol. It is not intended for individuals with type 1 diabetes or diabetic ketoacidosis. If you have type 2 diabetes and a BMI less than 27, Mounjaro® cannot be prescribed for weight loss.

Treatment starts at a low dose and increases every four weeks. The starting dose is 2.5 mg once a week for four weeks, then increasing every four weeks until the recommended dose of 15 mg a week is reached. The clinical team will review your weight with every order to ensure optimal dosing. Continued prescription requires a weight loss of around 5% of your initial body weight after a specified period.

Mounjaro® is one of the most effective weight loss treatments, with studies showing an average weight loss of 20.9% over 36 weeks and 25.3% over 88 weeks. It has been shown to be twice as effective as Wegovy® and Ozempic® in a study of people with type 2 diabetes on metformin.

Store Mounjaro® in the refrigerator at 2-8°C. It can be kept unrefrigerated for up to 21 days, but it is recommended to return the pen to the fridge after each use. Do not freeze Mounjaro®.